Adenosine A1 receptor signaling inhibits BK channels through a PKCα-dependent mechanism in mouse aortic smooth muscle

腺苷 A1 受体信号通过 PKCα 依赖性机制抑制小鼠主动脉平滑肌中的 BK 通道

阅读:8
作者:Ss Kunduri, Gm Dick, Ma Nayeem, Sj Mustafa

Abstract

Adenosine receptors (AR; A1, A2A, A2B, and A3) contract and relax smooth muscle through different signaling mechanisms. Deciphering these complex responses remains difficult because relationships between AR subtypes and various end-effectors (e.g., enzymes and ion channels) remain to be identified. A1AR stimulation is associated with the production of 20-hydroxyeicosatetraenoic acid (20-HETE) and activation of protein kinase C (PKC). 20-HETE and PKC can inhibit large conductance Ca2+/voltage-sensitive K+ (BK) channels that regulate smooth muscle contraction. We tested the hypothesis that activation of A1AR inhibits BK channels via a PKC-dependent mechanism. Patch clamp recordings and Western blots were performed using aortae of wild type (WT) and A1AR knockout (A1KO) mice. There were no differences in whole-cell K+ current or α and β1 subunits expression between WT and A1KO. 20-HETE (100 nM) inhibited BK current similarly in WT and A1KO mice. NECA (5'-N-ethylcarboxamidoadenosine; 10 μM), a non-selective AR agonist, increased BK current in myocytes from both WT and A1KO mice, but the increase was greater in A1KO (52±15 vs. 17±3%; p<0.05). This suggests that A1AR signaling negatively regulates BK channel activity. Accordingly, CCPA (2-chloro-N(6)-cyclopentyladenosine; 100 nM), an A1AR-selective agonist, inhibited BK current in myocytes from WT but not A1KO mice (81±4 vs. 100±7% of control; p<0.05). Gö6976 (100 nM), a PKCα inhibitor, abolished the effect of CCPA to inhibit BK current (99±3% of control). These data lead us to conclude that, in aortic smooth muscle, A1AR inhibits BK channel activity and that this occurs via a mechanism involving PKCα.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。